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The disease risk score is a summary score that can be used to control for confounding with a potentially large set
of covariates. While less widely used than the exposure propensity score, the disease risk score approach might
be useful for novel or unusual exposures, when treatment indications or exposure patterns are rapidly changing, or
whenmore is known about the nature of how covariates cause disease than is known about factors influencing pro-
pensity for the exposure of interest. Focusing on the simple case of a binary point exposure, we describe amarginal
structural model for estimation of risk (or prevalence) ratios. The proposed model incorporates the disease risk
score as an offset in a regressionmodel, and it yields an estimate of a standardized risk ratio where the target popu-
lation is the exposed group. Simulations are used to illustrate the approach, and an empirical example is provided.
Confounder control based on the proposedmethodmight be a useful alternative to approaches based on the expo-
sure propensity score, or as a complement to them.
cohort studies; cross-sectional studies; regression analysis; standardization
Abbreviations: IPE, inverse probability of exposure; RR, risk ratio; SMR, standardizedmortality ratio.
One approach to control for confounding of an exposure-
outcome association by measured covariates commences by
summarizing the relationship between these covariates and the ex-
posure or outcome variable of interest, deriving a 1-dimensional
variable. A widely used example of this approach is the expo-
sure propensity score, which describes a person’s probability of
exposure (called “treatment”) given their observed covariate
pattern (1, 2). The exposure propensity score can be used for
confounder control by matching, stratification, or regression
model adjustment for the score, and it can be used to derive a
weight that can be applied in a weighted regression (3–5).
An alternative summary variable, less widely used by epide-
miologists (6), is the disease risk score,which describes a person’s
risk of disease given their observed covariate pattern (7). Glynn
et al. (7) and Arbogast and Ray (8) provide useful overviews of
the history and use of disease risk scores. The approach com-
mences by developing a model to predict the outcome as a func-
tion of known confounders, which becomes the basis for the
disease risk score. Hansen (9) has shown that stratification
on a disease risk score can yield consistent effect estimates
with a meaningful counterfactual interpretation, and Stürmer
et al. (10) have illustrated that under conditions typically
encountered in empirical data analyses, models that control
for confounding by regression adjustment for a disease risk
score yield similar estimates and confidence intervals to those
obtained by matching on an exposure propensity score. Use of
the disease risk score for confounder control could be appeal-
ing in settings in which estimation of the exposure propensity
score is problematic, such as when the exposure of interest is
novel or very rare (8, 11) or when the pattern of exposure (or
treatment indication) is rapidly evolving (7). In practice, the
disease risk score has proved to be a useful tool, most notably
in comparative effectiveness research (6, 7).
In this work, we focused on cohort analyses in which we
wished to estimate the risk or prevalence ratio for a contrast
defined by a point exposure. Building upon the disease risk
score approach, we describe a novel way to estimate the para-
meters of a marginal structural model using a disease risk score.
The approach could be a useful tool for flexible regression
modeling in some commonly encountered research settings.
METHODS
Consider a study of n individuals in which Y denotes a binary
outcome variable. LetX denote a binary exposure variable of pri-
mary interest and Z = {Z1, . . ., Zk} denote the k covariates that
are potential confounders of the associations between X and Y.
These study data might be organized in a data set with 1 record
per person.
Suppose that the investigator wants to compare the occurrence
of Y between groups defined by X, controlling for confounding
by Z. Specifically, assume that the investigator wants to estimate
the exposure effect by comparing the exposed group mean (risk
of the outcome) with the expected mean of counterfactual out-
comes in a groupwith the sameZ distribution as the exposed (2).
This comparison can be summarized as a risk ratio, E(Y|X = 1)/
E(Y0|Z = z, X = 1), with a target population of the exposed
group, where the potential outcome under the absence of ex-
posure is denoted Y0. Note that we are interested in an estimate
that is standardized to the covariate distribution in the exposed
population,
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for all individuals i. Therefore, given observed study data Y, X,
and Z, we can estimate disease risk score, F(Z), for each study
member.
Amarginal structural model based on the disease risk
score
Suppose that the data for this study of n individuals are sorted
in descending order by X, such that the first m records represent
people for whom X = 1 and the remaining n−m records repre-
sent people for whom X = 0. Using these data, we can readily




1 , and, under counterfactual
consistency and the causal identification conditions given by
Robins et al. (5), we can calculate E(Y0|Z = z, X = 1) as




1 , and these quantities can be used to derive the
desired risk ratio, E(Y|X = 1)/E(Y0|Z = z, X = 1).
An estimate of the standardized risk ratio can be obtained by
fitting a generalized linearmodel with log link and Poisson distri-
bution by including the log of the disease risk score as an offset,
( ( = | = )) = β + β + ( ( = ))Z zY X x x Flog Pr 1 log ,0 1
where βe 1 is an estimate of the desired standardized ratio mea-
sure, while β0 converges to 0 when F(Z = z) is estimated by a
regression model fitted to the empirical data for the unexposed
group. This model could be equivalently framed as a weighted
Poisson regression in which the disease risk score is included
as a weight in a log-linear regression, if one transforms the
dependent variable, Y, for each subject to be Y/F(Z). Estimation
of robust confidence intervals (14) is recommended given
the 2-stage regression (first estimation of disease risk score and
second fitting the marginal structural model). InWebAppendix 1
(available at https://academic.oup.com/aje) we provide illustrative
SAS (SAS Institute, Inc., Cary, North Carolina) code to obtain
risk ratios aswell as associated robust confidence intervals.
Simulation example
We used simulated data under a cohort study design to
demonstrate the implementation of the proposed approach.
Data were simulated for 1,000 cohort studies with 10,000
people in each cohort. In each simulation, we generated 10
covariates, denoted Z1–Z10. Among these, Z1–Z4 were con-
founders associated with both exposure and outcome, Z5–Z7
were exposure predictors, and Z8–Z10 were outcome predic-
tors. Z1, Z3, Z5, Z6, Z8, Z9 were random binary variables, and
the others were continuous variables assigned as the absolute
value of a standard normal random variables with zero mean
and unit variance. The relationships between variables follow
the structure described by Lee et al. (15), with correlations
induced between several of the variables (Web Figure 1). We
generated a random binary exposure, X, with exposure preva-
lence of approximately 10%; we encoded dependence of X on
covariates by specifying that X took a value of 1 with probability
similar to other familiar standardized estimators such as the stan-
dardized mortality ratio (SMR) (12, 13). Such analyses estimate 
the effect of the exposure among the exposed, which often cor-
responds to the group targeted for interventions, particularly for 
novel treatments that might be concentrated in a unique subset 
of the population. This standardized ratio is unconfounded by Z. 
If there is effect measure modification by Z, this standardized 
ratio offers a useful marginal estimate of the effect of exposure 
in a population that has the covariate distribution observed 
among the exposed study subjects; in the absence of effect mea-
sure modification, the effect of the exposure among the exposed 
is equal to the effect of the exposure in the total population.
Disease risk score
The disease risk score, F(Z), is a function of a vector of co-
variates, Z, that confers conditional independence between 
the potential outcome under the absence of exposure, Y0, and 
Z (i.e., Y0 ⊥ Z|F(Z)). Under our proposed approach, F(Z) is  
estimated by a regression model fitted to the empirical data 
for the unexposed group; assuming a binary outcome vari-
able, the disease risk score can be estimated as the expected 
value of Y0 given Z. Some authors have suggested that this 
function could be estimated using data for the entire cohort 
(i.e., exposed and unexposed) by including statistical terms 
for the product of exposure and covariates (9). Here, we pro-
pose to just use data for the unexposed group to limit potential 
for model misspecification (e.g., the need to model exposure 
effect modification). While rare outcomes often motivate 
case-control designs, rare exposures often motivate cohort 
studies, and a rare exposure typically implies a relatively large 
group of unexposed cohort members among whom it might 
be possible to reliably model the disease risk score. For the 
case of a single binary regressor variable, Z = z, the disease 
risk score could be estimated by fitting a logistic model to the
1/(1 + exp(−(−0.1–1 × Z1−0.5 × Z2−0.5 × Z3−0.5 × Z4−0.5 ×
Z5−0.5 × Z6−0.5 × Z7))).
We generated a random binary outcome Y in which we en-
coded dependence of the outcome on X and covariates. In simu-
lation scenario 1, Y took a value of 1 with probability exp(−1 +
1 × X−0.5 × Z1−0.1 × Z2−0.5 × Z3−0.1 × Z4−0.5 × Z8−0.5 ×
Z9−0.1 × Z10). In simulation scenario 2, Y took a value of 1 with
probability exp(−1+ 1 × X−0.5 × Z1−0.1 × Z2−0.5 × Z3−0.1 ×
Z4−0.5 × Z8−0.5 × Z9−0.1 × Z10 + 0.5 × X × Z1). Note that in
our first simulation scenario there are no products of X and
covariates, while in the second simulation scenario there is a
product of X and Z1 when generating the data. Therefore, in
the first simulation the risk ratio is homogeneous across levels
of covariates, while in the second it is not. In the first simula-
tion scenario, the average risk ratio among the exposed equals
the average risk ratio in the total study population, while in the
second scenario it does not.
We estimated the disease risk score by fitting a regression
model to predict Y as a function of Z1–Z10 among the unexposed
(X = 0), including each covariate as amain effect in the regression
model (and not including any terms for products of covariates).
We used the method described in this work (and SAS (SAS Insti-
tute, Inc.) code inWebAppendix 1) to obtain a marginal estimate
of the risk ratio where the target population is the exposed group
by fitting a general linear regression model for Y as a function of
X with log link, Poisson distribution, including the natural log of
the disease risk score as an offset. For comparison we also esti-
mated the effect of X on Y using marginal structural log binomial
models (Web Appendix 2), with robust variance and using
weights derived from a model for exposure propensity (16).
A logistic model was fitted to each simulated cohort to pre-
dict X as a function of Z1, Z2 . . ., Z10, including each covari-
ate as a main effect in the regression model (and not
including any terms for products of covariates). The pre-
dicted probability of exposure from the fitted model is the
propensity score. For comparability with results obtained
using our proposed disease risk score–based approach, we
constructed SMR weights to estimate the risk ratio where the
target population is the exposed group (4, 17); exposed
cohort members are given a weight of 1, while unexposed
cohort members are given weights that are defined as the ratio
of the estimated propensity score to 1minus the estimated propen-
sity score. We also constructed stabilized inverse-probability-of-
exposure (IPE) weights to estimate the risk ratio where the target
population is the total study population; exposed cohort members
are given a weight defined as the ratio of the marginal probability
of exposure to the estimated propensity score, while unexposed
cohort members are given aweight defined as the ratio of 1minus
themarginal probability of exposure to 1minus the estimated pro-
pensity score.
In each analysis, we summarized results from 1,000 simu-
lated cohorts by computing the mean log risk ratio (log(RR)),
the estimated standard deviation of the 1,000 log(RR)s, and
the average estimated robust standard error of the log(RR) from
the GENMOD procedure in SAS (SAS Institute, Inc.), available
in versions 9.0 and thereafter. Additional simulations illustrating
scenarios varying simulations conditions are included in Web
Appendix 3.
Empirical example
We used data from the 2012 North Carolina Live Birth Cer-
tificate to illustrate this approach. We selected an example
involving a large cohort with an exposure and outcome that
were common enough to allow us to reliably estimate models
for the disease risk score and the exposure propensity score
for the purposes of comparison. The outcome of interest, pre-
term birth, was defined as a live birth during the 17-week
interval beginning with the 21st week of gestation and ending
when 37 weeks of gestation are completed. The exposure of
primary interest was “smoke,” a dichotomous variable indicating
whether the mother reported smoking during the pregnancy. The
study population consisted of 64,616 singleton North Carolina
live births for which the birth and the entire 17-week risk period
for preterm birth (the 21st week of gestation through the 37th
week of gestation) occurred in 2012. Covariates, selected from
among variables that are available on theNorthCarolina birth cer-
tificate and were considered potential confounders, included age
(a continuous variable for maternal age in years), race (a 4-level
variable formaternal race/ethnicity: non-Hispanicwhite, Hispanic
white, African-American, other), and “pnc” (a dichotomous vari-
able for prenatal care during thefirst 20weeks of gestation).
We estimated disease risk scores by fitting a logistic regres-
sion model for preterm as the dependent variable, restricted
only to the unexposed population (i.e., individuals with smoke =
0); explanatory variables were age, age2, race, and pnc, and prod-
uct termswere included of the form age × pnc, age2 × pnc, age ×
race, and age2 × race. Linear and quadratic terms for age were
included to model nonlinearities in the association between
maternal age and the log risk of preterm. Higher-order polyno-
mial functions of age led to negligible improvement in model
fit. We fitted a log-linear Poisson regression model with the log
disease risk score as offset. For comparison, we also fittedmodels
weighted as a function of the exposure propensity score, using
SMR weights, and stabilized IPE weights. To calculate denomi-
nators for SMRweights in the unexposed and IPEweights for the
entire population, we estimated exposure propensity scores for
smoke as the dependent variable, with explanatory variables being
the same covariate vector used to estimate disease risk scores.
RESULTS
Simulations
In the first simulation scenario, the effect of exposure was
homogeneous across levels of covariates.Web Table 1 reports
the distributions of Z1–Z10 between subgroups defined by X in
the simulated cohorts. Table 1 reports mean log(RR) estimates
and standard errors based on simulations with 10,000 people
in each cohort. The crude estimate (log(RR) = 1.12) differs
from the value specified under the simulation setup (i.e., log
(RR) = 1.00). The mean of estimates obtained using the pro-
posed approach incorporating the log disease risk score as a
regression model offset was 1.00, conforming to the true value
specified under simulation scenario 1. The robust 95% confi-
dence intervals for the log(RR) estimates obtained using the
proposed approach appeared to have reasonable coverage,
Additional simulations were conducted to illustrate perfor-
mance of the proposed method under conditions of smaller
cohort size, lower prevalence of exposure, and nonlinearity/
nonadditivity of effects (Web Tables 2–4). Under the first
simulation scenario the effect of exposure was homogeneous
across levels of covariates. Given a smaller cohort size (1,000
observations per cohort), we found that the mean of estimates
obtained using the proposed approach was 1.00, as was the
mean of the estimates obtained using SMR-weighted regres-
sion models, conforming to the true value specified under the
simulation scenario. Similar results also were obtained when
we fitted a marginal structural log-binomial model using stabi-
lized IPE weights, although the mean of the estimates was
slightly less than 1.0. In simulations where the exposure prev-
alence was 5% or 2.5%, the mean of estimates obtained using
the proposed disease risk score approach, and obtained using
SMR-type weights, were 0.98, and 0.97, respectively (Web
Tables 3 and 4). When fitting a marginal structural log-binomial
model using IPE weights, the average log(RR) was 0.97 and
0.92; across the simulations, the average standard errors tended
to be larger under models based on IPEweighting than under the
proposed disease risk scoremodel.
Web Appendix 3 also reports simulation scenarios where
there was nonlinearity and/or nonadditivity in the effects of co-
variates while the fitted disease risk score and exposure propen-
sity score models included only linear and additive terms for
covariates. Overall, the 3methods performedwell in simulation
scenarios where the exposure prevalence was 10% or 5% (Web
Tables 2 and 3). The mean of estimates obtained using the pro-
posed disease risk score approach, and those obtained using
SMR-type weights, ranged from 0.97 to 1.00 under the scenarios
considered, and the average log(RR) estimates obtained using a
marginal structural log-binomial model with IPE weights ranged
from 0.96 to 1.00 under these scenarios. When the exposure
prevalence was 2.5% (Web Table 4), the mean of estimates ob-
tained using the proposed disease risk score approach, and those
obtained using SMR-type weights, ranged from 0.94 to 0.98
under the scenarios considered. Under a marginal structural log-
binomial model using IPE weights, the average log(RR) esti-
mates ranged from 0.90 to 0.92 under the scenarios considered;
across the simulations, the average standard errors tended to be
larger under models based on SMR-type and IPE weights than
under the proposed disease risk scoremodel.
Empirical example
In the North Carolina live birth data, the cumulative inci-
dence of preterm birth is 9.8%. The prevalence of the primary
exposure, maternal smoking (smoke), is 10.6%. In the observed
data, the average maternal age among those who reported smok-
ing (smoke = 1) was 2 years less than among those who did not
(smoke = 0), and 86%of thosewith smoke = 1 received prenatal
care while 92% of those with smoke = 0 received it. Using the
proposed disease risk score approach, the (standardized) risk
ratio for the association between smoking and preterm birth
was 1.37 (robust 95% confidence interval: 1.28, 1.46) (Table 2).
For comparison, we fitted a log-binomial model to the SMR-
weighted data for the association between smoking and preterm
birth, which yielded an estimate of the standardized risk ratio of
1.37 (robust 95% confidence interval: 1.27, 1.47), essentially
Table 1. Mean Estimated Log Risk Ratios, Empirical Standard
Error, and Average Estimated Standard Error for 1,000 CohortsWith
10,000Observations Each in a Simulation Study
Simulation log(RR) ESE ASEa
Scenario 1
Crude 1.12 0.05 0.05
Disease score (proposedmethod) 1.00 0.05 0.05
Exposure score (SMR-weighted) 1.00 0.06 0.05
Exposure score (IPE-weighted) 1.00 0.07 0.07
Scenario 2
Crude 1.32 0.05 0.05
Disease score (proposedmethod) 1.12 0.05 0.04
Exposure score (SMR-weighted) 1.12 0.05 0.05
Exposure score (IPE-weighted) 1.22 0.06 0.06
Abbreviations: ASE, average estimated standard error; ESE, 
empirical standard error; IPE, inverse probability of exposure; RR, 
risk ratio; SMR, standardized mortality ratio.
a For crude models, ASE is the average standard error estimated 
across 1,000 simulated cohorts. For weighted regression models, 
ASE is the average robust standard error.
encompassing the value specified under the simulation setup 
in 95.5% of simulations. For comparison, we fitted a mar-
ginal structural log-binomial model using weights derived 
from an exposure propensity score model; the mean of the 
estimates obtained using SMR-weighted regression models 
also conformed to the true value specified under the simula-
tion (log(RR) = 1.00). Similar results also were obtained 
when we fitted a marginal structural log-binomial model 
using stabilized IPE weights (average log(RR) = 1.00), re-
flecting the fact that the estimate of the standardized risk 
ratio obtained when the target population of the study is the 
exposed group (which is the estimate derived under the pro-
posed approach and is derived by SMR-type weighting using 
exposure propensity score–based weights) equals the estimate 
of the standardized risk ratio when the target population is the 
total population (which is the estimate derived under inverse 
probability of exposure weighting) when there is no modifica-
tion of the effect measure across levels of covariates. The mean 
stabilized IPE weight was 1.00, the minimum weight was 0.24, 
and the 5th, 25th, 50th, 75th, and 95th percentiles of weights were 
0.77, 0.94, 0.97, 1.03, and 1.21.
In simulation scenario 2, data were generated such that the 
risk ratio was heterogeneous across strata of Z1. The estimated 
standardized log(RR) from the regression model with the log 
disease risk score as offset was 1.12. Similarly, when we fitted 
a marginal structural model using weights derived from an ex-
posure propensity score model and SMR-type weighting, the 
average estimated standardized log risk ratio was 1.12. In con-
trast, fitting a model based on stabilized IPE weighting yielded 
an estimate of 1.22, which estimates the average treatment 
effect among the total population, which we expect to differ in 
simulation scenario 2 from an estimate of the standardized risk 
ratio when the target population is the exposed group, as obtained 
from the proposed model incorporating a disease risk score as 
offset.
identical to the disease risk score–basedmarginal structural model
estimate of the standardized risk ratio among the exposed. We
also fitted a log-binomial model to the IPE-weighted data for the
association between smoking and preterm birth, which yielded an
estimate of the standardized risk ratio of 1.46 (robust 95% confi-
dence interval: 1.32, 1.60), which is an estimate of the smoking
effect in the total population. The mean stabilized IPE weight
was 1.00, the minimum weight was 0.30, and the 5th, 25th,
50th, 75th, and 95th percentiles of weights were 0.77, 0.94, 0.98,
1.02, and 1.20.
DISCUSSION
Based on the variety of simulation settings we have con-
sidered, we found that the proposed approach yields a mar-
ginal estimate of the risk ratio that is equivalent to an estimate
obtained in an analysis using an SMR-typeweighted log-binomial
regressionmodel based on exposure propensity scores—namely a
marginal estimate of the risk ratio where the target population is
the exposed.We found that an IPE-weighted estimate of the aver-
age risk ratio in the total study population was not well estimated,
and we noted in simulations that as the exposure prevalence
diminished (from10% to 5% to 2.5%), the IPE-weighted estimate
tended to perform less well than the proposed disease risk score–
basedmethod. Also, the empirical standard error and average esti-
mated standard error for the IPE method tended to diverge from
each other and tended to be larger than the empirical standard
error and average estimated standard error obtained for the pro-
posed disease risk score–based method (Web Appendix 3). We
caution, however, that conclusions from our limited range of
simulation-based results are not conclusive. Moreover, in these
simulations we focused solely on results for the disease risk
score, SMR-type weighted, and IPE-weighted regression mod-
els quantified with robust standard errors, and we did not con-
sider comparability of bootstrap-based measures of precision. In
an empirical data analysis we found that an estimate of the associ-
ation of interest between maternal smoking and preterm birth ob-
tained using the proposed approach (i.e., incorporating the log
of the disease risk score as a regression model offset) yielded
an equivalent estimate of the standardized risk ratio to that ob-
tained from a weighted log-binomial regression with SMR-type
weights derived based on an exposure propensity score model.
In our proposed approach, we fitted a model to estimate the
disease risk score using information only for the unexposed,
for whom Y0 is observed under counterfactual consistency.
Scores are then extrapolated using this model to predict the
counterfactual disease risk for exposed individuals within the
cohort. Alternatively, this model could be fitted in the total
population by including the exposure of interest in the regres-
sion model (18); disease risk scores are then assigned to each
individual after setting treatment status to zero. Arbogast and
Ray (19) evaluated the performance of these two strategies
and found that if the disease risk score model is correctly spec-
ified, then confounding control tended to be better when the
score was modeled using the full cohort versus only within the
comparator subcohort. Another approach, and the one classi-
cally used in SMR analyses, is to estimate the disease risk
score in data for an external reference population.
Prior authors have described confounder control with the dis-
ease risk score implemented through matching, stratification, or
covariate adjustment (e.g., entering the score by means of indi-
cator terms for categories) (7–9). In the present study, we
describe an approach to estimation of a standardized risk ratio
(where the target population is the exposed group) by incorpo-
rating the log disease risk score as an offset in a regression
model. This avoids coarsening (as might occur when match-
ing, stratifying, or adjusting for categories defined by the dis-
ease risk score) or the need to specify a parametric form (as
occurs when including the disease risk score as a continuous
explanatory variable in a regression model). It was recently
noted that the epidemiologic literature provides no theory or
examples of methods for weighting on the disease risk score
(20). The present study fills that gap; we note that the approach
could be implemented by weighting on the disease risk score
(after appropriately transforming the outcome variable).
The disease risk score has been less widely used by epide-
miologists than the exposure propensity score (6). While there
might be historical (21, 22) as well as theoretical reasons for
this (7–9), one practical limitation of disease risk score–based
methods (comparedwith exposure propensity score–based ap-
proaches) is that it is not easy to assess balance of covariates in
a disease risk–based analysis, as can be readily done with ex-
posure propensity score–based approaches. For example, with
IPE-weighted marginal structural models, one can undertake a
simple assessment of covariate balance across exposure groups
using the weighted data. Despite such limitations, the proposed
disease risk score model might be appealing when one wishes
to obtain a standardized (i.e., marginal) estimate of association
and the exposure propensity score is difficult to estimate well.
Glynn et al. (7) reviewed study design features that influence
the value or feasibility of analyses using a disease risk score rel-
ative to using an exposure propensity score. One such setting is
when there is substantial historical information available to
help inform model development for the disease risk score,
while little is known about indications for the treatment or
exposure. Development of disease risk score models could
be informed by prior literature on the nature of how covariates
cause the disease of interest, which is useful if information
available for modeling the probability of exposure is sparse.
Another setting is when the exposure conditions, or indica-
tions for treatment, are rapidly evolving. Rare exposures for
small, or moderately sized, cohorts also can pose challenges
for estimation of the exposure propensity score (8). In addi-
tion, prior simulation studies have illustrated problems of bias
Table 2. Estimates of Association BetweenMaternal Smoking and
Preterm Birth Among 66,172 Live Births in North Carolina, 2012
Model RR 95%CIa
Crude 1.33 1.25, 1.43
Disease score (proposedmethod) 1.37 1.28, 1.46
Exposure score (SMR-weighted) 1.37 1.27, 1.47
Exposure score (IPE-weighted) 1.46 1.32, 1.60
Abbreviations: CI, confidence interval; IPE, inverse probability of
exposure; RR, risk ratio; SMR, standardizedmortality ratio.
a Robust confidence intervals were estimated to account for within-
subject correlation induced by weighting.
that can arise in exposure propensity score analyses when the
exposure is rare (11). For the proposed disease risk score
approach, rather than requiring exposed and unexposed at each
level of covariate, the disease risk score model requires only
positivity across the balancing disease risk score (often a weak-
er condition termed “risk positivity,” requiring no values of dis-
ease risk at which treatment is received or not received with
certainty) (19).
Prior authors have also suggested that the disease risk score
might be appealing when there are more than 2 exposures of
interest (7) or when the exposure of interest is polytomous or
continuous (8). Exposure propensity score modeling can get
complex in such situations, while in principle polytomous or
continuous exposure variables pose no additional problems
for the disease risk score–based models (because estimation of
a disease risk score is no more difficult in a cohort study where
the exposure of interest is a polytomous variable than it is if
the exposure is a dichotomous variable). However, if the expo-
sure of interest is not binary, but rather is a polytomous variable,
one needs to reflect carefully on interpretation of the estimates
that involve pair-wise comparisons with the reference group,
because different exposure groups might be standardized to dif-
ferent Z distributions. Consequently, to demonstrate the appli-
cability of disease risk scores for estimating a standardized
risk ratio for the average effect of exposure in the exposed, we
have focused in the present study on the simple case of a binary
exposure.
The proposed model-based standardization using the disease
risk score provides a potentially useful tool in cohort analysis
for estimation of risk or prevalence ratios. One can obtain com-
parable estimates to those derived using marginal structural
models with exposure propensity score–based weighting, yield-
ing a standardized estimate of the risk ratio where the target pop-
ulation is the exposed.
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